Ashlan Kunz Coyne, PharmD, MPH
Deciphering a Bacteria’s Drug Resistance to Develop Better Treatments
Summary
Infectious diseases are a global health challenge, especially those caused by bacteria that resist multiple antibiotics. One such bacterium, Stenotrophomonas maltophilia, is a growing concern in hospitals and communities, particularly for patients with weakened immune systems, like those undergoing treatment for blood cancers. S. maltophilia is difficult to treat due to its natural resistance to many antibiotics and the lack of effective management guidelines. Our research aims to develop better treatments for S. maltophilia by studying how various antibiotic regimens affect it. We will use advanced models to simulate human treatments and test these in mice to find the most effective antibiotics. By examining the bacterium’s response at the molecular level, we hope to better understand its resistance mechanisms. Ultimately, our goal is to discover new ways to treat these infections and improve outcomes for vulnerable patients.
Watch a Q&A with Ashlan
The PhRMA Foundation Faculty Starter Grant in Translational Medicine acknowledges the potential impact of my work on optimizing antimicrobial PK/PD against resistant bacterial infections, aiming to enhance outcomes in vulnerable patients. With deep appreciation for the financial support, this grant empowers my lab to achieve significant advancements in the field.
